Vai al contenuto

Pubblicazioni scientifiche

Dott. Ferdinando D'Amico

  1. Hindryckx P, Laukens D, D’Amico F, Danese S. Unmet Needs in IBD: the Case of Fatigue. Clin Rev Allergy Immunol. 2017 Aug 29. doi: 10.1007/s12016-017-8641-4. IF: 6.442
  2. Spadaccini M, Hassan C, Maselli R, D’Amico F, Lamonaca L, Craviotto V, Repici A. Efficacy and safety of SIC-8000 (Eleview®) for submucosal injection for endoscopic mucosal resection and endoscopic submucosal dissection in an in vivo porcine model. Dig Liver Dis. 2017 Dec 2. pii: S1590- 8658(17)31313-0. doi: 10.1016/j.dld.2017.11.017. IF: 3.287
  3. Fiorino G, D’Amico F, Italia A, Gilardi D, Furfaro F, Danese S. Jak inhibitors: novel developments in management of ulcerative colitis. Best Pract Res Clin Gastroenterol. 2018 Feb-Apr; 32-33.89-93. IF: 3.583
  4. Anderloni A, Fugazza A, Auriemma F, Maia L, Maselli R, Troncone E, D’Amico F, Repici A. Cautery-Tipped Lumen Apposing Metal Stent Placement Through the Mesh of an Indwelling Duodenal Self-Expanding Metal Stent. Am J Gastroenterol. 2018 Apr 23. doi: 10.1038/s41395-018- 0040-9. IF: 10.241
  5. Anderloni A, Fugazza A, Auriemma F, Maselli R, D’Amico F, Troncone E, Repici A. Intrabiliary resection of metastasis originating from colorectal carcinoma during direct peroral cholangioscopy: a new tool for biliary palliation. Endoscopy 2018 Apr; 50(4):E97-E98.doi:10.1055/s-0044-100487. IF:
  6. 381 6. D’Amico F, Fiorino G, Furfaro F, Allocca M, Danese S. Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials. Expert opin Investig Drugs. 2018 July; 27(7):595-599 IF: 4.031 
  7. Danese S, D’Amico F, Bonovas S, Peyrin-Biroulet L. Positioning tofacitinib in the treatment algorithm of moderate to severe ulcerative colitis. Inflamm Bowel Dis. 2018 Sep 15;24(10)2106-2112. IF: 4.005
  8. Anderloni A, Fugazza A, Troncone E, Auriemma F, Carrara S, Semeraro R, Maselli R, Di Leo M, D’Amico F, Sethi A, Repici A. Single-stage EUS-guided choledochoduodenostomy using a lumenapposing metal stent for malignant distal biliary obstruction. Gastrointest Endosc. 2019 Jan;89(1):69- 76. doi: 10.1016/j.gie.2018.08.047. IF: 6.890
  9. Spadaccini M, Fugazza A, Troncone E, Craviotto V, D’Amico F, Lamonaca L, Anderloni A, Repici A. EUS-Guided Biliary Drainage Versus ERCP for the Primary Palliation of Malignant Biliary Obstruction: An Unfair Comparison. Am J Gastroenterol. 2019 Jan;114(1):174. doi: 10.1038/s41395- 018-0371-6. IF: 10.171
  10. D’Amico F, Maselli R, Galtieri PA, Spadaccini M, Repici A. Endoscopic submucosal dissection of a rectal nongranular laterally spreading tumor with the use of a new endoscopic platform. VideoGIE. 2019 Feb 8;4(3):140-141. doi: 10.1016/j.vgie.2018.12.011.
  11. D’Amico F, Roda G, Peyrin-Biroulet L, Danese S. Anti-adhesion Molecules in IBD: Does Gut Selectivity Really Make the Difference? Curr Pharm Des. 2019;25(1):19-24. doi: 10.2174/1381612825666190307165703. IF: 2.208
  12. Anderloni A, Auriemma F, Fugazza A, Troncone E, Maia L, Maselli R, Carrara S, D’Amico F, Belletrutti PJ, Repici A. Direct peroral cholangioscopy in the management of difficult biliary stones: a new tool to confirm common bile duct clearance. Results of a preliminary study. J Gastrointestin Liver Dis. 2019 Mar;28(1):89-94. doi: 10.15403/jgld.2014.1121.281.bil. IF: 2.351 
  13. D’Amico F, Fiorino G, Peyrin-Biroulet L, Danese S. Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing. Immunotherapy. 2019 May;11(7):565-575. doi: 10.2217/imt-2018-0209. IF: 2.964
  14. D’Amico F. Parigi TL, Fiorino G, Peyrin-Biroulet L, Danese S. Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. Therap Adv Gastroenterol. 2019 May 16;12:1756284819848631 IF: 3.520
  15. Spadaccini M, Fuccio L, Lamonaca L, Frazzoni L, Maselli R, Di Leo M, Galtieri PA, Craviotto V, D’Amico F, Hassan C, Repici A. Underwater EMR for colorectal lesions: a systematic review with meta-analysis (with video). Gastrointest Endosc. 2019 Jun;89(6):1109-1116.e4. doi: 10.1016/j.gie.2018.10.023. IF: 6.890
  16. Anderloni A, Fugazza A, Troncone E, Auriemma F, Carrara S, Semeraro R, Maselli R, Di Leo M, D’Amico F, Sethi A, Repici A. Response. Gastrointest Endosc. 2019 Oct;90(4):697-698. doi: 10.1016/j.gie.2019.06.036. IF: 6.890 
  17. Spadaccini M, Bhandari P, Maselli R, Spaggiari P, Alkandari AA, Varytimiadis L, Semeraro R, Di Leo M, Galtieri PA, Craviotto V, Lamonaca L, D’Amico F, Attardo S, Brambilla T, Sharma P, Hassan C, Repici A. Multi-band mucosectomy for neoplasia in patients with Barrett’s esophagus: in vivo comparison between two different devices. Surg Endosc. 2019 Oct 4. doi: 10.1007/s00464-019- 07150-w. IF: 3.149 
  18. D’Amico F, Pouillon L, Argollo M, et al. Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group. Dig Liver Dis 2019. IF: 3.570 Curriculum Vitae Ferdinando D’Amico Page 5 / 14
  19. D’Amico F, Fiorini G, Tursi A, et al. Efficacy of a New Nutraceutical Formulation in Patients with Symptomatic Uncomplicated Diverticular Disease (SUDD): a Prospective Observational Study. J Gastrointest Liver Dis JGLD 2019;28:49–52. IF: 2.351
  20. Fauny M, D’Amico F, Bonovas S, et al. Fecal calprotectin for the diagnosis of bowel inflammation in patients with rheumatological diseases: a systematic review. J Crohns Colitis 2019. IF: 8.658 
  21. D’Amico F, Baumann C, Rousseau H, et al. Phase 1, 2 and 3 trials in inflammatory bowel diseases: a practical guide for the non-specialist. J Crohns Colitis 2020. IF: 9.071
  22. D’Amico F, Danese S, Peyrin-Biroulet L. Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins? Expert Opin Biol Ther 2020:1–9. IF: 4.388
  23. D’Amico F, Bonovas S, Danese S, Peyrin-Biroulet L. Review article: faecal calprotectin and histologic remission in ulcerative colitis. Aliment Pharmacol Ther. 2020;51(7):689-698. doi:10.1111/apt.15662 IF: 8.171
  24. Pellegatta G, Spadaccini M, Lamonaca L, et al. Evaluation of Human Esophageal Epithelium Permeability in Presence of Different Formulations Containing Hyaluronic Acid and Chondroitin Sulphate. Med Devices (Auckl). 2020;13:57-66. Published 2020 Mar 4. doi:10.2147/MDER.S234810
  25. D’Amico F, Baumgart DC, Danese S, Peyrin-Biroulet L. Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management. Clin Gastroenterol Hepatol. 2020;18(8):1663-1672. doi:10.1016/j.cgh.2020.04.001 IF: 11.382 
  26. Peyrin-Biroulet C, D’Amico F, Peyrin-Biroulet L. Will COVID-19 infection be less severe in ulcerative colitis than in Crohn’s patients due to a lower rate of smokers? [published online ahead of print, 2020 Apr 18]. J Crohns Colitis. 2020;jjaa077. doi:10.1093/ecco-jcc/jjaa077 IF: 9.071 
  27. Allocca M, Fiorino G, Furfaro F, et al. Maintaining the Quality Standards of Care for Inflammatory Bowel Disease Patients During the COVID-19 Pandemic. Clin Gastroenterol Hepatol. 2020;18(8):1882-1883. doi:10.1016/j.cgh.2020.04.028 IF: 11.382 
  28. D’Amico F, Peyrin-Biroulet L, Danese S. Inflammatory Bowel Diseases and COVID-19: The Invisible Enemy. Gastroenterology. 2020;158(8):2302-2304. doi:10.1053/j.gastro.2020.04.032 IF: 22.682 
  29. Parigi TL, D’Amico F, Danese S. Upadacitinib for Crohn’s disease and ulcerative colitis treatment: hitting the selective JAKpot [published online ahead of print, 2020 Apr 17]. Gastroenterology. 2020;S0016-5085(20)30517-5. doi:10.1053/j.gastro.2020.04.034 IF: 22.682 
  30. D’Amico F, Pugliese N, Peyrin-Biroulet L, Danese S. Efficacy of anti-TNFα drugs in patients with stricturing Crohn’s disease. Expert Rev Gastroenterol Hepatol. 2020;14(5):347-353. doi:10.1080/17474124.2020.1759417 IF: 3.869 
  31. D’Amico F, Danese S, Peyrin-Biroulet L; ECCO COVID taskforce. Inflammatory Bowel Disease Management During the Coronavirus-19 Outbreak: A Survey From the European Crohn’s and Colitis Organization. Gastroenterology. 2020;159(1):14-19.e3. doi:10.1053/j.gastro.2020.04.059 IF: 22.682
  32. D’Amico F, Nancey S, Danese S, Peyrin-Biroulet L. A practical guide for faecal calprotectin measurement: myths and realities [published online ahead of print, 2020 May 11]. J Crohns Colitis. 2020;jjaa093. doi:10.1093/ecco-jcc/jjaa093 IF: 9.071
  33. D’Amico F, Rahier JF, Leone S, Peyrin-Biroulet L, Danese S. Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey. Lancet Gastroenterol Hepatol. 2020;5(7):631-632. doi:10.1016/S2468-1253(20)30151-5 IF: 18.486 D’Amico F, Fiorino G, Furfaro F, et al. Patient’s profiling for therapeutic management of inflammatory bowel disease: a tailored approach [published online ahead of print, 2020 May 28]. Expert Rev Gastroenterol Hepatol. 2020;1-9. doi:10.1080/17474124.2020.1772057 IF: 3.869 
  34. D’Amico F, Peyrin-Biroulet L, Danese S. Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic. J Clin Med. 2020;9(5):1536. Published 2020 May 19. doi:10.3390/jcm9051536 IF: 4.242
  35. D’Amico F, Parigi TL, Bonovas S, Peyrin-Biroulet L, Danese S. Long-term safety of approved biologics for ulcerative colitis [published online ahead of print, 2020 Jun 8]. Expert Opin Drug Saf. 2020;1-9. doi:10.1080/14740338.2020.1773430 IF: 4.250
  36. D’Amico F, Chateau T, Laurent V, Danese S, Peyrin-Biroulet L. Which MRI Score and Technique Should Be Used for Assessing Crohn’s Disease Activity?. J Clin Med. 2020;9(6):1691. Published 2020 Jun 2. doi:10.3390/jcm9061691 IF: 4.242
  37. Furfaro F, Vuitton L, Fiorino G, et al. SFED recommendations for IBD endoscopy during COVID19 pandemic: Italian and French experience. Nat Rev Gastroenterol Hepatol. 2020;17(8):507- 516. doi:10.1038/s41575-020-0319-3 IF: 46.802 
  38. D’Amico F, Peyrin-Biroulet L, Vandromme L, et al. Motivation to pursue anti-TNFα treatment in patients with Crohn’s disease – the SPACE motivation study [published online ahead of print, 2020 Jun 9]. Dig Liver Dis. 2020;S1590-8658(20)30238-3. doi:10.1016/j.dld.2020.05.032 IF: 4.088 Curriculum Vitae Ferdinando D’Amico Page 6 / 14
  39. D’Amico F, Danese S, Peyrin-Biroulet L. Reply [published online ahead of print, 2020 Jun 20]. Clin Gastroenterol Hepatol. 2020;S1542-3565(20)30849-1. doi:10.1016/j.cgh.2020.06.038 IF: 11.382 
  40. D’Amico F, Peyrin-Biroulet L, Danese S. JAK or GUT Selectivity: Tipping the Balance for Efficacy and Safety in Ulcerative Colitis [published online ahead of print, 2020 Jun 24]. J Crohns Colitis. 2020;jjaa074. doi:10.1093/ecco-jcc/jjaa074 IF: 9.071
  41. D’Amico F, Peyrin-Biroulet L, Danese S. Tofacitinib for Acute Severe Colitis: When the going Gets Tough, the Tough Get Going. J Crohns Colitis. 2020;14(7):883-885. doi:10.1093/eccojcc/jjaa028 IF: 9.071
  42. D’Amico F, Wexner SD, Vaizey CJ, Gouynou C, Danese S, Peyrin-Biroulet L. Tools for fecal incontinence assessment: lessons for inflammatory bowel disease trials based on a systematic review [published online ahead of print, 2020 Jul 17]. United European Gastroenterol J. 2020;2050640620943699. doi:10.1177/2050640620943699 IF: 4.623 
  43. D’Amico F, Danese S, Peyrin-Biroulet L. Adaptive Designs: Lessons for Inflammatory Bowel Disease Trials. J Clin Med. 2020;9(8):E2350. Published 2020 Jul 23. doi:10.3390/jcm9082350 IF: 4.242
  44. Fauny M, Moulin D, D’Amico F, et al. Paradoxical gastrointestinal effects of interleukin-17 blockers [published online ahead of print, 2020 Jul 21]. Ann Rheum Dis. 2020;annrheumdis2020-217927. doi:10.1136/annrheumdis-2020-217927 IF: 19.103
  45. D’Amico F, Danese S, Peyrin-Biroulet L. Systematic review on IBD patients with COVID-19: it is time to take stock [published online ahead of print, 2020 Aug 7]. Clin Gastroenterol Hepatol. 2020;S1542-3565(20)31080-6. IF: 11.382
  46. Guillo L, D’Amico F, Serrero M, et al. Assessment of extraintestinal manifestations in inflammatory bowel diseases: A systematic review and a proposed guide for clinical trials [published online ahead of print, 2020 Aug 10]. United European Gastroenterol J. 2020;2050640620950093. IF: 4.623
  47. D’Amico F, Amato A, Iannone A, et al. Risk of Covert Submucosal Cancer in Patients With Granular Mixed Laterally Spreading Tumors [published online ahead of print, 2020 Jul 17]. Clin Gastroenterol Hepatol. 2020;S1542-3565(20)30986-1. IF: 11.382
  48. Parigi TL, D’Amico F, Peyrin-Biroulet L, Danese S. Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13 [published online ahead of print, 2020 Aug 31]. Expert Opin Biol Ther. 2020;1-10. IF: 4.388
  49.  Solitano V, D’Amico F, Zacharopoulou E, Peyrin-Biroulet L, Danese S. Early Intervention in Ulcerative Colitis:
  50. Ready for Prime Time?. J Clin Med. 2020;9(8):E2646. Published 2020 Aug 14. IF: 4.242
  51. D’Amico F, Netter P, Baumann C, et al. Setting up a Virtual Calprotectin Clinic in Inflammatory Bowel Diseases: Literature Review and Nancy Experience. J Clin Med. 2020;9(9):E2697. Published 2020 Aug 20. IF: 4.242
  52. Chateau T, D’Amico F, Zallot C, Mathieu N, Peyrin-Biroulet L. Crohn’s Disease Only Visible on Small Bowel Capsule Endoscopy: A New Entity. Dig Dis Sci. 2020;10.1007/s10620-020-06553- 3. IF: 3.199
  53. D’Amico F, Solitano V, Peyrin-Biroulet L, Danese S. Nocebo effect and biosimilars in inflammatory bowel diseases: what’s new and what’s next? [published online ahead of print, 2020 Aug 28]. Expert Opin Biol Ther. 2020;10.1080/14712598.2020.1817374. IF: 4.388
  54. Solitano V, Fiorino G, D’Amico F, Peyrin-Biroulet L, Danese S. Thrombosis in IBD in the era of JAK inhibition. Curr Drug Targets. 2020 Sep 2. IF: 3.465 
  55. Solitano V, D’Amico F, Fiorino G, Paridaens K, Peyrin-Biroulet L, Danese S. Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis. J Clin Med. 2020 Sep 8;9(9):E2905. IF: 4.242
  56. Muller M, D’Amico F, Bonovas S, Danese S, Peyrin-Biroulet L. TNF inhibitors and risk of malignancy in patients with inflammatory bowel diseases: a systematic review. J Crohns Colitis. 2020 Sep 11:jjaa186. IF: 9.071
  57. Vaillant S, Guillo L, Michot N, D’Amico F, Germain A, Danese S, Baumann C, Rousseau H, Quilliot D, Peyrin-Biroulet L. Predictors for short bowel syndrome in Crohn’s disease. Dig Liver Dis. 2020 Sep 14:S1590-8658(20)30448-5. IF: 4.088
  58. Solitano V, D’Amico F, Fiorino G, Peyrin-Biroulet L, Danese S. Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice. Expert Rev Clin Immunol. 2020 Sep 29:1-10. IF: 4.473 
  59. Guillo L, Rabaud C, Choy EH, D’Amico F, Danese S, Ng SC, Peyrin-Biroulet L. Herpes zoster and vaccination strategies in inflammatory bowel diseases: a practical guide. Clin Gastroenterol Hepatol. 2020 Oct 17:S1542-3565(20)31440-3. IF: 11.382
  60. Allocca M, Chaparro M, Gonzalez HA, Bosca-Watts MM, Palmela C, D’Amico F, Zacharopoulou E, Kopylov U, Ellul P, Bamias G, Ntelis V, Lahat A, Mantzaris GJ, Papaconstantinou I, Katsanos Curriculum Vitae Ferdinando D’Amico Page 7 / 14 K, Uspenskaya Y, Christodoulou D, Ben Horin S, Peyrin-Biroulet L, Torres J, Sebastian S, Gisbert JP, Danese S, Fiorino G. Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study. J Clin Med. 2020 Oct 31;9(11):3533. IF: 4.242
  61. Solitano V, D’Amico F, Correale C, Peyrin-Biroulet L, Danese S. Thiopurines and non-melanoma skin cancer: partners in crime in inflammatory bowel diseases. Br Med Bull. 2020 Dec 15;136(1):107-117 IF: 4.291
  62. Weislinger L, Guillo L, D’Amico F, Danese S, Achit H, Ayav C, Guillemin F, Peyrin-Biroulet L, Frimat L. Knowledge of 5-aminosalicylic acid nephrotoxicity and adherence to kidney function monitoring of patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2020 Nov 30. IF: 2.568
  63. D’Amico F, Peyrin-Biroulet L, Danese S, Fiorino G. New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming? Curr Opin Pharmacol. 2020 Dec;55:141-150. IF: 5.547
  64. Turner D, Ricciuto A, Lewis A, D’Amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, Schölmerich J, Bemelman W, Danese S, Mary JY, Rubin D, Colombel JF, Peyrin-Biroulet L, Dotan I, Abreu MT, Dignass A; International Organization for the Study of IBD. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021 Apr;160(5):1570- 1583. IF: 33.883
  65. Guillo L, D’Amico F, Danese S, Peyrin-Biroulet L. Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: a systematic literature review. J Crohns Colitis. 2020 Dec 24:jjaa260. IF: 9.071
  66. Petitpain N, D’Amico F, Yelehe-Okouma M, Jouzeau JY, Netter P, Peyrin-Biroulet L, Gillet P. IL17 Inhibitors and Inflammatory Bowel Diseases: A Postmarketing Study in Vigibase. Clin Pharmacol Ther. 2021 Jan 7. IF: 7.051
  67. D’Amico F, Peyrin-Biroulet L, Danese S. Reply. Gastroenterology. 2021 Apr;160(5):1881. doi: 10.1053/j.gastro.2020.12.072. Epub 2021 Jan 5. IF: 33.883
  68. D’Amico F, Rabaud C, Peyrin-Biroulet L, Danese S. SARS-CoV-2 vaccination in IBD: more pros than cons. Nat Rev Gastroenterol Hepatol. 2021 Apr;18(4):211-213. doi: 10.1038/s41575-021- 00420-w. IF: 73.082
  69. Laurain PA, Guillo L, D’Amico F, Netter P, Danese S, Baumann C, Luc A, Clerc-Urmes I, Spyridon S, Peyrin-Biroulet L. Incidence of and Risk Factors for Colorectal Strictures in Ulcerative Colitis: A Multicenter Study. Clin Gastroenterol Hepatol. 2021 Jan 22:S1542- 3565(21)00078-1. IF: 13.576
  70. D’Amico F, Peyrin-Biroulet L, Danese S. Reply. Gastroenterology. 2021 May;160(6):2223-2224. doi: 10.1053/j.gastro.2021.02.001. Epub 2021 Feb 4. PMID: 33548235; PMCID: PMC7857985. IF: 33.883
  71. Caron B, D’Amico F, Danese S, Peyrin-Biroulet L. Endpoints for perianal Crohn’s disease trials: past, present, and future. J Crohns Colitis. 2021 Feb 7:jjab026. doi: 10.1093/ecco-jcc/jjab026. IF: 10.020
  72. Guillo L, D’Amico F, Achit H, Ayav C, Guillemin F, Danese S, Frimat L, Peyrin-Biroulet L. Kidney function monitoring to prevent 5-aminosalicylic acid nephrotoxicity: What the gastroenterologist should know. Dig Liver Dis. 2021 Feb 6:S1590-8658(21)00021-9. IF: 5.165
  73. D’Amico F, Guillo L, Baumann C, Danese S, Peyrin-Biroulet L. Histological disease activity measured by the Nancy index is associated with long-term outcomes in patients with ulcerative colitis. J Crohns Colitis. 2021 Apr 5:jjab063. doi: 10.1093/ecco-jcc/jjab063. IF: 10.020
  74. Solitano V, D’Amico F, Allocca M, Fiorino G, Zilli A, Loy L, Gilardi D, Radice S, Correale C, Danese S, Peyrin-Biroulet L, Furfaro F. Rediscovering histology: what is new in endoscopy for inflammatory bowel disease? Therap Adv Gastroenterol. 2021 Apr 16;14:17562848211005692 IF: 4.802
  75. D’Amico F, Rubin DT, Kotze PG, Magro F, Siegmund B, Kobayashi T, Olivera PA, Bossuyt P, Pouillon L, Louis E, Domènech E, Ghosh S, Danese S, Peyrin-Biroulet L. International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. United European Gastroenterol J. 2021 May 7. doi: 10.1002/ueg2.12069. IF: 6.866
  76. D’Amico F, Solitano V, Aletaha D, Hart A, Magro F, Selmi C, Ng SC, Al Awadhi S, Choy E, Schulze-Koops H, Bossuyt P, Olivera PA, Kotze PG, Ghosh S, Peyrin-Biroulet L, Danese S. Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus. Autoimmun Rev. 2021 May 8:102849. doi: 10.1016/j.autrev.2021.102849. IF: 17.390 
  77. Geyl S, Guillo L, Laurent V, D’Amico F, Danese S, Peyrin-Biroulet L. Transmural healing as a therapeutic goal in Crohn’s disease: a systematic review. Lancet Gastroenterol Hepatol. 2021 Curriculum Vitae Ferdinando D’Amico Page 8 / 14 Aug;6(8):659-667. IF: 45.042 
  78. Solitano V, Alfarone L, D’Amico F, Peyrin-Biroulet L, Danese S. IBD goes home: from telemedicine to self-administered advanced therapies. Expert Opin Biol Ther. 2021 Jun 30:1-13. IF: 5.589 
  79. Grandmougin A, D’Amico F, Remen T, Danese S, Bonneton M, Galloy MA, Peyrin-Biroulet L, Laurent V. Role of Cross-Sectional Imaging in Pediatric Inflammatory Bowel Disease. Dig Dis Sci. 2021 Jun 22. IF: 3.487 
  80. Abdelnaby H, Ndiaye NC, D’Amico F, Fouad AM, Hassan S, Elshafey A, Al Hashash W, Faisal M, Alshamali Y, Al-Taweel T, Peyrin-Biroulet L. NOD2/CARD15 polymorphisms (P268S, IVS8+158, G908R, L1007fs, R702W) among Kuwaiti patients with Crohn’s disease: A casecontrol study. Saudi J Gastroenterol. 2021 Jul-Aug;27(4):249-256. IF: 3.214
  81. Furfaro F, Dal Buono A, Allocca M, D’Amico F, Zilli A, Gabbiadini R, Danese S. Bowel Ultrasound in Inflammatory Bowel Disease: How Far in the Grayscale? Life (Basel). 2021 Jul 4;11(7):649. IF: 3.253
  82. Fugazza A, Troncone E, Amato A, Tarantino I, Iannone A, Donato G, D’Amico F, Mogavero G, Amata M, Fabbri C, Radaelli F, Occhipinti P, Repici A, Anderloni A. Difficult biliary cannulation in patients with distal malignant biliary obstruction: An underestimated problem? Dig Liver Dis. 2021 Aug 4:S1590-8658(21)00378-9. IF: 5.165 
  83. Caron B, D’Amico F, Danese S, Peyrin-Biroulet L. Cluster Randomized Trials: Lessons for Inflammatory Bowel Disease Trials. J Crohns Colitis. 2021 Aug 14:jjab149. IF: 10.020 
  84. Allocca M, Craviotto V, Dell’Avalle C, Furfaro F, Zilli A, D’Amico F, Bonovas S, Peyrin-Biroulet L, Fiorino G, Danese S. Bowel ultrasound score is accurate in assessing response to therapy in patients with Crohn’s disease. Aliment Pharmacol Ther. 2021 Nov 15. doi: 10.1111/apt.16700. IF: 9.524 
  85. D’Amico F, Magro F, Peyrin-Biroulet L, Danese S. Positioning filgotinib in the treatment algorithm of moderate to severe ulcerative colitis. J Crohns Colitis. 2021 Nov 16:jjab206. doi: 10.1093/ecco-jcc/jjab206. IF: 10.020 
  86. Graffigna G, Bosio C, Pagnini F, Volpato E, Previtali E, Leone S, D’Amico F, Armuzzi A, Danese S. Promoting psycho-social wellbeing for engaging inflammatory bowel disease patients in their care: an Italian consensus statement. BMC Psychol. 2021 Nov 28;9(1):186. IF: 2.588
  87. D’Amico F, Allocca M, Fiorino G. Positioning ozanimod in ulcerative colitis: restoring leukocyte traffic under control. Gastroenterology. 2021 Dec 8:S0016-5085(21)04063-4. IF: 33.883
  88. Alfarone L, Dal Buono A, Craviotto V, Zilli A, Fiorino G, Furfaro F, D’Amico F, Danese S, Allocca M. Cross-Sectional Imaging Instead of Colonoscopy in Inflammatory Bowel Diseases: Lights and Shadows. J Clin Med. 2022 Jan 12;11(2):353. IF: 3.9 
  89. D’Amico F, Zilli A, Fiorino G. Endoscopy and histology in inflammatory bowel diseases patients: Complementary or alternatives? United European Gastroenterol J. 2022 Jan 22. IF: 6.0
  90. Furfaro F, Dal Buono A, Sicuso C, Allocca M, D’Amico F, Zilli A, Fiorino G, Gabbiadini R, Danese S. Carcinomas in inflammatory bowel disease: a narrative review on diagnostic imaging techniques. Chin Clin Oncol. 2022 Jan 24:cco-21-98. IF: 2.8 
  91. Gabbiadini R, D’Amico F, De Marco A, Terrin M, Zilli A, Furfaro F, Allocca M, Fiorino G, Danese S. Colorectal Cancer Surveillance in Patients with Inflammatory Bowel Diseases: Chromoendoscopy or Non-Chromoendoscopy, That Is the Question. J Clin Med. 2022 Jan 20;11(3):509. IF: 3.9 
  92. Solitano V, Zilli A, Franchellucci G, Allocca M, Fiorino G, Furfaro F, D’Amico F, Danese S, Al Awadhi S. Artificial Endoscopy and Inflammatory Bowel Disease: Welcome to the Future. J Clin Med. 2022 Jan 24;11(3):569. IF: 3.9 
  93. Parigi TL, Mastrorocco E, Da Rio L, Allocca M, D’Amico F, Zilli A, Fiorino G, Danese S, Furfaro F. Evolution and New Horizons of Endoscopy in Inflammatory Bowel Diseases. J Clin Med. 2022 Feb 7;11(3):872. IF: 3.9
  94. Dell’Avalle C, D’Amico F, Gabbiadini R, Dal Buono A, Pugliese N, Zilli A, Furfaro F, Fiorino G, Allocca M, Peyrin-Biroulet L, Danese S. JAK inhibitors in crohn’s disease: ready to go? Expert Opin Investig Drugs. 2022 Feb;31(2):145-161. IF: 6.1 
  95. Vespa E, D’Amico F, Sollai M, Allocca M, Furfaro F, Zilli A, Dal Buono A, Gabbiadini R, Danese S, Fiorino G. Histological Scores in Patients with Inflammatory Bowel Diseases: The State of the Art. J Clin Med. 2022 Feb 11;11(4):939. IF: 3.9 
  96. Allocca M, Dell’Avalle C, Craviotto V, Furfaro F, Zilli A, D’Amico F, Bonovas S, Peyrin-Biroulet L, Fiorino G, Danese S. Predictive value of Milan ultrasound criteria in ulcerative colitis: A prospective observational cohort study. United European Gastroenterol J. 2022 Mar 1. IF: 6.0 
  97. Mandarino FV, Barchi A, Fanti L, D’Amico F, Azzolini F, Esposito D, Biamonte P, Lauri G, Danese S. Endoscopic vacuum therapy for post-esophagectomy anastomotic dehiscence as rescue treatment: a single center case series. Esophagus. 2022 Mar 28. doi: 10.1007/s10388-022- 00912-x. IF: 2.4 Curriculum Vitae Ferdinando D’Amico Page 9 / 14
  98. Parigi TL, D’Amico F, Abreu MT, Rubin DT, Dignass A, Dotan I, Jairath V, Magro F, PeyrinBiroulet L, Ghosh S, Danese S. Difficult-to-treat inflammatory bowel disease: results from a global ustey. Lancet Gastroenterol Hepatol. 2022 May;7(5):390-391. IF: 35.7
  99. Bretto E, D’Amico F, Fiore W, Tursi A, Danese S. Lactobacillus paracasei CNCM I 1572: A Promising Candidate for Management of Colonic Diverticular Disease. J Clin Med. 2022 Mar 30;11(7):1916. IF: 3.9 
  100. D’Amico F, Peyrin-Biroulet L, Danese S. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022 May 5;386(18):1767-1768. doi: 10.1056/NEJMc2202778. IF: 158.5
  101. D’Amico F, Peyrin-Biroulet L, Danese S. Ustekinumab in Crohn’s Disease: New Data for Positioning in Treatment Algorithm. J Crohns Colitis. 2022 May 11;16(Supplement_2):ii30-ii41. doi: 10.1093/ecco-jcc/jjac011. IF: 8.0 
  102. D’Amico F, Tasopoulou O, Fiorino G, Zilli A, Furfaro F, Allocca M, Sileri P, Spinelli A, PeyrinBiroulet L, Danese S. alogical Therapy in Operated Crohn’s Disease Patients Is Associated With a Lower Rate of Endoscopic Recurrence and Improved Long-term Outcomes: A Single-center Experience. Inflamm Bowel Dis. 2022 May 28:izac110. doi: 10.1093/ibd/izac110. IF: 4.9
  103. Napolitano M, D’Amico F, Ragaini E, Peyrin-Biroulet L, Danese S. Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy. Drug Des Devel Ther. 2022 Jun 17;16:1897-1913. doi: 10.2147/DDDT.S340459. IF: 4.8
  104. Wils P, Caron B, D’Amico F, Danese S, Peyrin-Biroulet L. Abdominal Pain in Inflammatory Bowel Diseases: A Clinical Challenge. J Clin Med. 2022 Jul 22;11(15):4269. doi: 10.3390/jcm11154269. IF: 3.9
  105. D’Amico F, Danese S, Fiorino G. Could small molecules be used in combination with biologics for inflammatory bowel disease? Expert Rev Clin Immunol. 2022 Aug 2:1-3. doi: 10.1080/1744666X.2022.2104713. IF: 4.4 
  106. Caron B, D’Amico F, Jairath V, Netter P, Danese S, Peyrin-Biroulet L. lala methods for benefit-risk assessment: lessons for inflammatory bowel disease drugs. J Crohns Colitis. 2022 Aug 11:jjac113. doi: 10.1093/ecco-jcc/jjac113. IF: 8.0 
  107. Laland M, François M, D’Amico F, Zallot C, Brochard C, Dewitte M, Siproudhis L, Peyrin-Biroulet L, Bouguen G. Identification of the optimal medical and surgical management for patients with perianal fistulising Crohn’s disease. Colorectal Dis. 2022 Aug 25. doi: 10.1111/codi.16314. IF: 3.4
  108. Caron B, Jairath V, D’Amico F, Paridaens K, Magro F, Danese S, Peyrin-Biroulet L. Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review. United European Gastroenterol J. 2022 Aug 27. doi: 10.1002/ueg2.12283. IF: 6.0 
  109. D’Amico F, Fiorino G, Solitano V, Massarini E, Guillo L, Allocca M, Furfaro F, Zilli A, Bonovas S, Magro F, Peyrin-Biroulet L, Danese S. Ulcerative colitis: Impact of early disease clearance on long-term outcomes -A multicenter cohort study. United European Gastroenterol J. 2022 Sep;10(7):775-782. doi: 10.1002/ueg2.12288. IF: 6.0
  110. Vieujean S, D’Amico F, Netter P, Danese S, Peyrin-Biroulet L. Landscape of new drugs and targets in inflammatory bowel disease. United European Gastroenterol J. 2022 Sep 16. doi: 10.1002/ueg2.12305. IF: 6.0
  111. Furfaro F, Gabbiadini R, D’Amico F, Zilli A, Buono AD, Allocca M, Fiorino G, Danese S. Gastrointestinal system, COVID-19 and potential mechanisms associated with coagulopathy. Curr Drug Targets. 2022 Sep 22. doi: 10.2174/1389450123666220922095913. IF: 3.2 
  112. D’Amico F, Peyrin-Biroulet L, Danese S. Is Selectivity the JAKpot Winner for Inflammatory Bowel Disease Treatment? Gastroenterology. 2022 Sep 22:S0016-5085(22)01065-4. doi: 10.1053/j.gastro.2022.09.011. IF: 29.4 
  113. Mannucci A, D’Amico F, El Saadi A, Peyrin-Biroulet L, Danese S. Filgotinib for moderately to severely active ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2022 Oct 24. doi: 10.1080/17474124.2022.2138857. IF: 3.9
  114. Furfaro F, D’Amico F, Zilli A, Craviotto V, Aratari A, Bezzio C, Spinelli A, Gilardi D, Radice S, Saibeni S, Papi C, Peyrin-Biroulet L, Danese S, Fiorino G, Allocca M. Non-invasive assessment of postoperative disease recurrence in Crohn’s Disease: a multicenter, prospective cohort study on behalf of the IG-IBD. Clin Gastroenterol Hepatol. 2022 Dec 12:S1542-3565(22)01131-4. doi: 10.1016/j.cgh.2022.11.039. IF: 12.6
  115. Caron B, Jairath V, D’Amico F, Al Awadhi S, Dignass A, Hart AL, Kobayashi T, Kotze PG, Magro F, Siegmund B, Paridaens K, Danese S, Peyrin-Biroulet L. International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients. Medicina (Kaunas). 2023 Jan 16;59(1):183. doi: 10.3390/medicina59010183. IF: 2.6
  116. Vieujean S, De Vos M, D’Amico F, Paridaens K, Daftary G, Dudkowiak R, Peyrin-Biroulet L, Danese S. Inflammatory bowel disease meets fertility: A physician and patient survey. Dig Liver Dis. 2023 Jan 23:S1590-8658(23)00160-3. doi: 10.1016/j.dld.2023.01.149. IF: 4.5 Curriculum Vitae Ferdinando D’Amico Page 10 / 14 
  117. D’Amico F, Magro F, Caron B, Dignass A, Jairath V, Hart A, Kotze PG, Paridaens K, Awadhi SA, Kobayashi T, Siegmund B, Peyrin-Biroulet L, Danese S. iSTART-II: An Update on the i Support Therapy-Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mildto-Moderate Ulcerative Colitis. J Clin Med. 2023 Feb 1;12(3):1142. doi: 10.3390/jcm12031142. IF:3.9
  118. Massimino L, Palmieri O, Facoetti A, Fuggetta D, Spanò S, Lamparelli LA, D’Alessio S, Cagliani S, Furfaro F, D’Amico F, Zilli A, Fiorino G, Parigi TL, Noviello D, Latiano A, Bossa F, Latiano T, Pirola A, Mologni L, Piazza RG, Abbati D, Perri F, Bonini C, Peyrin-Biroulet L, Malesci A, Jairath V, Danese S, Ungaro F. Gut virome-colonising Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo. Gut. 2023 Feb 14:gutjnl-2022-328375. doi: 10.1136/gutjnl-2022-328375. IF: 24.5 
  119. Mandarino FV, Barchi A, D’Amico F, Fanti L, Azzolini F, Viale E, Esposito D, Rosati R, Fiorino G, Bemelman WA, Elmore U, Barbieri L, Puccetti F, Testoni SGG, Danese S. Endoscopic Vacuum Therapy (EVT) versus Self-Expandable Metal Stent (SEMS) for Anastomotic Leaks after Upper Gastrointestinal Surgery: Systematic Review and Meta-Analysis. Life (Basel). 2023 Jan 19;13(2):287. doi: 10.3390/life13020287. IF: 3.2
  120. Neurath L, D’Amico F, Danese S. Emerging drugs for the treatment of moderately to severely active ulcerative colitis: review of phase II and III clinical trials. Expert Opin Emerg Drugs. 2023 Mar;28(1):27-42. doi: 10.1080/14728214.2023.2186399. IF: 3.4
  121. Goetsch A, D’Amico F, Allocca M, Fiorino G, Furfaro F, Zilli A, Parigi TL, Radice S, Peyrin-Biroulet L, Danese S. Advances in pharmacotherapy for ulcerative colitis: a focus on JAK1 inhibitors. Expert Opin Pharmacother. 2023 May;24(7):849-861. doi: 10.1080/14656566.2023.2200931. IF: 3.4
  122. Allocca M, Dell’Avalle C, Furfaro F, Zilli A, D’Amico F, Peyrin-Biroulet L, Fiorino G, Danese S. Early intestinal ultrasound predicts long-term endoscopic response to biologics in ulcerative colitis. J Crohns Colitis. 2023 Apr 21:jjad071. doi: 10.1093/ecco-jcc/jjad071. IF: 8.0
  123. Lauri G, D’Amico F, Allocca M, Palumbo D, Della-Torre E, De Cobelli F, Doglioni C, Arcidiacono PG, Capurso G, Danese S. Ustekinumab as induction and maintenance therapy in patients with inflammatory bowel disease and type II autoimmune pancreatitis: report of two cases. J Crohns Colitis. 2023 Apr 22:jjad072. doi: 10.1093/ecco-jcc/jjad072. IF: 8.0 
  124. D’Amico F, Vieujean S, Caron B, Peyrin-Biroulet L, Danese S. Risk-Benefit of IBD Drugs: A Physicians and Patients Survey. J Clin Med. 2023 Apr 24;12(9):3094. doi: 10.3390/jcm12093094. IF: 3.9 
  125. D’Amico F, Peyrin-Biroulet L, Danese S. Disease clearance in ulcerative colitis: Is the ultimate therapeutic target? United European Gastroenterol J. 2023 Jul 3. doi: 10.1002/ueg2.12436. IF: 6.0
  126. Parigi TL, D’Amico F, Abreu MT, Dignass A, Dotan I, Magro F, Griffiths AM, Jairath V, Iacucci M, Mantzaris GJ, O’Morain C, Reinisch W, Sachar DB, Turner D, Yamamoto T, Rubin DT, PeyrinBiroulet L, Ghosh S, Danese S. Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting. Lancet Gastroenterol Hepatol. 2023 Sep;8(9):853-859. doi: 10.1016/S2468-1253(23)00154-1. IF: 35.7 
  127. D’Amico F, Magro F, Siegmund B, Kobayashi T, Kotze PG, Solitano V, Caron B, Al Awadhi S, Hart A, Jairath V, Dignass A, Peyrin-Biroulet L, Danese S. Disease Clearance as a New Outcome in Ulcerative Colitis: a Systematic Review and Expert Consensus. Inflamm Bowel Dis. 2023 Aug 7:izad159. doi: 10.1093/ibd/izad159. IF: 4.9
  128. Bencardino S, D’Amico F, Faggiani I, Bernardi F, Allocca M, Furfaro F, Parigi TL, Zilli A, Fiorino G, Peyrin-Biroulet L, Danese S. Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis. J Clin Med. 2023 Jul 30;12(15):5014. doi: 10.3390/jcm12155014. IF: 3.9
  129. .Biamonte P, D’Amico F, Fasulo E, Barà R, Bernardi F, Allocca M, Zilli A, Danese S, Furfaro F. New Technologies in Digestive Endoscopy for Ulcerative Colitis Patients. Biomedicines. 2023 Jul 29;11(8):2139. doi: 10.3390/biomedicines11082139. IF: 4.7 
  130. D’Amico F, Peyrin-Biroulet L, Danese S. Disease Clearance is not Synonymous with Cure. Inflamm Bowel Dis. 2023 Oct 5:izad236. doi: 10.1093/ibd/izad236. IF: 4.9
  131. D’Amico F, Solitano V, Magro F, Olivera PA, Halfvarson J, Rubin D, Dignass A, Al Awadhi S, Kobayashi T, Queiroz NSF, Calvo M, Kotze PG, Ghosh S, Peyrin-Biroulet L, Danese S. Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus. J Clin Med. 2023 Oct 3;12(19):6350. doi: 10.3390/jcm12196350. IF: 3.9
  132. Vieujean S, Lindsay JO, D’Amico F, Ahuja V, Silverberg MS, Sood A, Yamamoto-Furusho JK, Nagahori M, Watanabe M, Koutroubakis IE, Foteinogiannopoulou K, Avni Biron I, Walsh A, Outtier A, Nordestgaard RLM, Abreu MT, Dubinsky M, Siegel C, Louis E, Dotan I, Reinisch W, Danese S, Rubin DT, Peyrin-Biroulet L. Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases (IBD): Real World Results from the International Organization for the study of Curriculum Vitae Ferdinando D’Amico Page 11 / 14 IBD. J Crohns Colitis. 2023 Oct 21:jjad180. doi: 10.1093/ecco-jcc/jjad180. IF: 8.0
  133. Awadhi SA, Alboraie M, Albaba EA, Almutairdi A, Alsaad M, Azzam N, Barakat H, D’Amico F, Danese S, El Kady M, Ghoneim H, Hamoudi W, Jazzar A, Mosli M, Shehab H, Sneineh AA. Treatment of Patients with Mild to Moderate Ulcerative Colitis: A Middle East Expert Consensus. J Clin Med. 2023 Nov 4;12(21):6929. doi: 10.3390/jcm12216929. IF: 3.9
  134. Barchi A, D’Amico F, Zilli A, Furfaro F, Parigi TL, Fiorino G, Peyrin-Biroulet L, Danese S, Dal Buono A, Allocca M. Recent advances in the use of ultrasound in Crohn’s disease. Expert Rev Med Devices. 2023 Jul-Dec;20(12):1119-1129. doi: 10.1080/17434440.2023.2283166. IF: 3.1
  135. D’Amico F, Massironi S, Allocca M, Danese S. Advancing transmural remission as a treatment target in Crohn’s disease: The future of tight-control strategy? United European Gastroenterol J. 2023 Nov 16. doi: 10.1002/ueg2.12495. IF: 6.0
  136. Fanizza J, D’Amico F, Lauri G, Martinez-Dominguez SJ, Allocca M, Furfaro F, Zilli A, Fiorino G, Parigi TL, Radice S, Peyrin-Biroulet L, Danese S. The role of filgotinib in ulcerative colitis and Crohn’s disease. Immunotherapy. 2023 Nov 27. doi: 10.2217/imt-2023-0116. IF: 2.8 
  137. D’Amico F, Fasulo E, Jairath V, Paridaens K, Peyrin-Biroulet L, Danese S. Management and treatment optimization of patients with mild to moderate ulcerative colitis. Expert Rev Clin Immunol. 2023 Dec 7. doi: 10.1080/1744666X.2023.2292768. IF: 4.4
  138. Solitano V, Facheris P, Petersen M, D’Amico F, Ortoncelli M, Aletaha D, Olivera PA, Bieber T, Ramiro S, Ghosh S, D’Agostino MA, Siegmund B, Chary-Valckenaere I, Hart A, Dagna L, Magro F, Felten R, Kotze PG, Jairath V, Costanzo A, Kristensen LE, Biroulet LP, Danese S. Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study. Autoimmun Rev. 2023 Dec 19:103504. doi: 10.1016/j.autrev.2023.103504. IF: 13.6
  139. Parigi TL, Allocca M, Furfaro F, D’Amico F, Zilli A, Dal Buono A, Gabbiadini R, Bonovas S, Armuzzi A, Danese S, Fiorino G. Treat-to-Target and Regular Surveillance of Inflammatory Bowel Disease Are Associated with Low Incidence and Early-Stage Detection of Malignancies: A Retrospective Cohort Study. Cancers (Basel). 2023 Dec 8;15(24):5754. doi: 10.3390/cancers15245754. IF: 5.2
  140. Solitano V, D’Amico F, Da Rio L, Peyrin-Biroulet L, Danese S. The European Perspective and History on Biosimilars for the Treatment of Inflammatory Bowel Diseases. Crohns Colitis 360. 2021 Feb 23;3(1):otab012. doi: 10.1093/crocol/otab012.
  141. Barchi A, Dal Buono A, D’Amico F, Furfaro F, Zilli A, Fiorino G, Parigi TL, Peyrin-Biroulet L, Danese S, Allocca M. Leaving behind the Mucosa: Advances and Future Directions of Intestinal Ultrasound in Ulcerative Colitis. J Clin Med. 2023 Dec 8;12(24):7569. doi: 10.3390/jcm12247569. IF: 3.9
  142. Fasulo E, D’Amico F, Osorio L, Allocca M, Fiorino G, Zilli A, Parigi TL, Danese S, Furfaro F. The Management of Postoperative Recurrence in Crohn’s Disease. J Clin Med. 2023 Dec 25;13(1):119. doi: 10.3390/jcm13010119. IF: 3.9
  143. Fanizza J, D’Amico F, Lusetti F, Fasulo E, Allocca M, Furfaro F, Zilli A, Parigi TL, Radice S, Peyrin-Biroulet L, Danese S, Fiorino G. The Role of IL-23 Inhibitors in Crohn’s Disease. J Clin Med. 2023 Dec 30;13(1):224. doi: 10.3390/jcm13010224. IF: 3.9
  144. Allocca M, Catalano G, Savarino EV, Chaparro M, Levartovsky A, Michalopoulos G, Viazis N, Fousekis FS, Psistakis A, Noviello D, Nascimento CND, Caron B, Kitsou V, Bamias G, García MJ, Zacharopoulou E, Foteinogiannopoulou K, D’Amico F, Koutroubakis I, Ellul P, Tzouvala M, Peyrin-Biroulet L, Torres J, Caprioli F, Karmiris K, Theodoropoulou A, Katsanos KH, Christodoulou DK, Mantzaris GJ, Kopylov U, Gisbert JP, Danese S, Magro F, Carla F, Fiorino G. Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study. United European Gastroenterol J. 2024 Feb 28. doi: 10.1002/ueg2.12492.
  145. Bernardi F, D’Amico F, Bencardino S, Faggiani I, Fanizza J, Zilli A, Parigi TL, Allocca M, Danese S, Furfaro F. Gut Microbiota Metabolites: Unveiling Their Role in Inflammatory Bowel Diseases and Fibrosis. Pharmaceuticals (Basel). 2024 Mar 7;17(3):347. doi: 10.3390/ph17030347.
  146. .Allocca M, Dell’Avalle C, Zilli A, Furfaro F, D’Amico F, Jairath V, Rubin DT, Peyrin-Biroulet L, Fiorino G, Danese S. Ultrasound remission after biologic induction and long-term endoscopic remission in Crohn’s disease: a prospective cohort study. EClinicalMedicine. 2024 Mar 21;71:102559. doi: 10.1016/j.eclinm.2024.102559.
  147. . Lusetti F, D’Amico F, Allocca M, Furfaro F, Zilli A, Fiorino G, Parigi TL, Radice S, Peyrin-Biroulet L, Danese S. Positioning risankizumab in the treatment algorithm of moderate-to-severe Crohn’s disease. Immunotherapy. 2024 Apr 17. doi: 10.2217/imt-2023-0219.
  148. D’Amico F, Lusetti F, Peyrin-Biroulet L, Danese S. MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations. Dig Liver Dis. 2024 May 4:S1590- 8658(24)00713-8. doi: 10.1016/j.dld.2024.04.012.
  149. Faggiani I, D’Amico F, Bernardi F, Bencardino S, Allocca M, Furfaro F, Parigi TL, Zilli A, Fiorino G, Curriculum Vitae Ferdinando D’Amico Page 12 / 14 Peyrin-Biroulet L, Danese S. Evaluating the pharmacokinetics of upadacitinib for the treatment of moderate-to-severe Crohn’s disease. Expert Opin Drug Metab Toxicol. 2024 May;20(5):297-305. doi: 10.1080/17425255.2024.2349711.
  150. D’Amico F, Jairath V, Paridaens K, Peyrin-Biroulet L, Danese S. Drug Optimization in Patients with Mild-to-Moderate Ulcerative Colitis: A Global Survey. J Clin Med. 2024 Apr 24;13(9):2510. doi: 10.3390/jcm13092510.
  151. D’Amico F, Gomollón F, Bamias G, Magro F, Targownik L, Leitner C, Heatta-Speicher T, Michelena N, Kolterer S, Lapthorn J, Kauffman L, Dignass A; IBD PODCAST investigators. Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice-Real-world evidence from the inflammatory bowel diseases-podcast study. United European Gastroenterol J. 2024 May 11. doi: 10.1002/ueg2.12572. 
  152. D’Amico F, Peyrin-Biroulet L, Danese S. Benefits of Biosimilars in the Management of Patients with Inflammatory Bowel Disease: An International Survey. J Clin Med. 2024 May 24;13(11):3069. doi: 10.3390/jcm13113069. 
  153. D’Amico F, Massimino L, Palmieri G, Buono AD, Gabbiadini R, Caron B, Moreira P, Silva I, Bosca-Watts M, Innocenti T, Dragoni G, Bezzio C, Zilli A, Furfaro F, Saibeni S, Chaparro M, García MJ, Michalopoulos G, Viazis N, Mantzaris GJ, Ellul P, Gisbert JP, Magro F, PeyrinBiroulet L, Armuzzi A, Ungaro F, Danese S, Fiorino G, Allocca M. An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study. Eur J Clin Invest. 2024 Jul 9:e14283. doi: 10.1111/eci.14283.
  154. Cicerone C, D’Amico F, Allocca M, Zilli A, Parigi TL, Danese S, Furfaro F. A Comprehensive Multidisciplinary Approach to Diagnosing Chronic Inflammatory Bowel Diseases: Integration of Clinical, Endoscopic, and Imaging Modalities. Diagnostics (Basel). 2024 Jul 16;14(14):1530. doi: 10.3390/diagnostics14141530.
  155. Bernardi F, Ungaro F, D’Amico F, Zilli A, Parigi TL, Massimino L, Allocca M, Danese S, Furfaro F. The Role of Viruses in the Pathogenesis of Immune-Mediated Gastro-Intestinal Diseases. Int J Mol Sci. 2024 Jul 30;25(15):8301. doi: 10.3390/ijms25158301.
  156. Faggiani I, D’Amico F, Furfaro F, Zilli A, Parigi TL, Cicerone C, Fiorino G, Peyrin-Biroulet L, Danese S, Allocca M. Small Bowel Cancer in Crohn’s Disease. Cancers (Basel). 2024 Aug 21;16(16):2901. doi: 10.3390/cancers16162901.
  157. Faggiani I, Fanizza J, D’Amico F, Allocca M, Zilli A, Parigi TL, Barchi A, Danese S, Furfaro F. Extraintestinal Manifestations in Inflammatory Bowel Disease: From Pathophysiology to Treatment. Biomedicines. 2024 Aug 13;12(8):1839. doi: 10.3390/biomedicines12081839.
  158. D’Amico F, Magro F, Dignass A, Al Awadhi S, Gutierrez Casbas A, Queiroz NSF, Rydzewska G, Duk Ye B, Ran Z, Hart A, Jairath V, Fiorino G, Peyrin-Biroulet L, Danese S. Practical management of mild-to-moderate ulcerative colitis: an international expert consensus. Expert Rev Gastroenterol Hepatol. 2024 Aug;18(8):421-430. doi: 10.1080/17474124.2024.2397650.
  159. Parigi TL, Massimino L, Carini A, Gabbiadini R, Bertoli P, Allocca M, Bezzio C, Dal Buono A, D’Amico F, Furfaro F, Loy L, Zilli A, Ungaro F, Jairath V, Peyrin-Biroulet L, Armuzzi A, Danese S. Prevalence, characteristics, management, and outcomes of difficult-to-treat inflammatory bowel disease. J Crohns Colitis. 2024 Sep 12:jjae145. doi: 10.1093/ecco-jcc/jjae145.
  160. Fanizza J, Bencardino S, Allocca M, Furfaro F, Zilli A, Parigi TL, Fiorino G, Peyrin-Biroulet L, Danese S, D’Amico F. Inflammatory Bowel Disease and Colorectal Cancer. Cancers (Basel). 2024 Aug 23;16(17):2943. doi: 10.3390/cancers16172943.
  161. Danese S, Fiorino G, Vicaut E, Paridaens K, Ugur A, Clark B, Vanasek T, Stepek D, D’Amico F, West R, Gilissen LPL, Wisniewska Jarosinka M, Drobinski P, Fronik G, Fic M, Walczak M, Kowalski M, Korczowski B, Wiatr M, Peyrin-Biroulet L. Clinical Trial: A Pragmatic Randomised Controlled Study to Assess the Effectiveness of Two Patient Management Strategies in Mild to Moderate Ulcerative Colitis-The OPTIMISE Study. J Clin Med. 2024 Aug 30;13(17):5147. doi: 10.3390/jcm13175147.
  162. Calabrese E, Onali S, Variola A, Ribaldone DG, Savarino EV, Viola A, Saibeni S, Conforti FS, Testa A, Latella G, Orlando A, Principi M, Privitera AC, Guerra M, Ceccarelli L, Mocci G, Boy D, Piccarozzi MA, Gualberti G, Marando F, Gemignani L, D’Amico F. Suboptimal disease control and contributing factors in Italian IBD patients: The IBD-PODCAST Study. Dig Liver Dis. 2024 Sep 18:S1590-8658(24)00957-5. doi: 10.1016/j.dld.2024.08.040. 
  163. Nicolò S, Faggiani I, Errico C, D’Amico F, Parigi TL, Danese S, Ungaro F. Translational characterization of immune pathways in inflammatory bowel disease: insights for targeted treatments. Expert Rev Clin Immunol. 2024 Sep 23:1-18. doi: 10.1080/1744666X.2024.2400300.
  164. Aprile F, Vangeli M, Allocca M, Zilli A, Argollo MC, D’amico F, Parigi TL, Danese S, Furfaro F. Gastrointestinal Ultrasound in Infectious Diseases: A Comprehensive Review. Medicina (Kaunas). 2024 Aug 27;60(9):1402. doi: 10.3390/medicina60091402.
  165. Fanizzi F, D’Amico F, Zanotelli Bombassaro I, Zilli A, Furfaro F, Parigi TL, Cicerone C, Fiorino G, Curriculum Vitae Ferdinando D’Amico Page 13 / 14 Peyrin-Biroulet L, Danese S, Allocca M. The Role of Fecal Microbiota Transplantation in IBD. Microorganisms. 2024 Aug 23;12(9):1755. doi: 10.3390/microorganisms12091755.
  166. Fanizzi F, Allocca M, Fiorino G, Zilli A, Furfaro F, Parigi TL, Peyrin-Biroulet L, Danese S, D’Amico F. Raising the bar in ulcerative colitis management. Therap Adv Gastroenterol. 2024 Nov 24;17:17562848241273066. doi: 10.1177/17562848241273066.
  167. Centanni L, Bencardino S, D’Amico F, Zilli A, Parigi TL, Allocca M, Danese S, Furfaro F. Targeting mucosal healing in Crohn’s disease: efficacy of novel pathways and therapeutic targets. Expert Opin Ther Targets. 2024 Nov;28(11):963-978. doi: 10.1080/14728222.2024.2433124. 
  168. Dominguez-Muñoz JE, Vujasinovic M, de la Iglesia D, Cahen D, Capurso G, Gubergrits N, Hegyi P, Hungin P, Ockenga J, Paiella S, Perkhofer L, Rebours V, Rosendahl J, Salvia R, Scheers I, Szentesi A, Bonovas S, Piovani D, Löhr JM; European PEI Multidisciplinary Group. European guidelines for the diagnosis and treatment of pancreatic exocrine insufficiency: UEG, EPC, EDS, ESPEN, ESPGHAN, ESDO, and ESPCG evidence-based recommendations. United European Gastroenterol J. 2024 Dec 5. doi: 10.1002/ueg2.12674.
  169. Bencardino S, Matichecchia CS, Fanizza J, Peyrin-Biroulet L, Della-Torre E, Danese S, D’Amico F. IgG4 in the gut: Gastrointestinal IgG4-related disease or a new subtype of inflammatory bowel disease. Autoimmun Rev. 2024 Dec 7;24(2):103720. doi: 10.1016/j.autrev.2024.103720.
  170. Bencardino S, Allocca M, Furfaro F, D’Amico F, Parigi TL, Danese S, Zilli A. Multiple Ileal and Colonic Stenoses: Is It Always Crohn’s Disease? J Crohns Colitis. 2024 Dec 16:jjae174. doi: 10.1093/ecco-jcc/jjae174.
  171. Fasulo E, D’Amico F, Zilli A, Furfaro F, Cicerone C, Parigi TL, Peyrin-Biroulet L, Danese S, Allocca M. Advancing Colorectal Cancer Prevention in Inflammatory Bowel Disease (IBD): Challenges and Innovations in Endoscopic Surveillance. Cancers (Basel). 2024 Dec 28;17(1):60. doi: 10.3390/cancers17010060.
  172. .Allocca M, D’Amico F, Fiorino G, Jairath V, Kucharzik T, Peyrin-Biroulet L, Danese S. Systematic Review on definitions of Intestinal Ultrasound Treatment Response and Remission in Inflammatory Bowel Disease. J Crohns Colitis. 2025 Jan 18:jjaf011. doi: 10.1093/ecco-jcc/jjaf011.
  173. Bernardi F, Fanizzi F, Parigi TL, Zilli A, Allocca M, Furfaro F, Peyrin-Biroulet L, Danese S, D’Amico F. Role of Probiotics in the Management of Patients with Ulcerative Colitis and Pouchitis. Microorganisms. 2024 Dec 25;13(1):19. doi: 10.3390/microorganisms13010019.
  174. Centanni L, Cicerone C, Fanizzi F, D’Amico F, Furfaro F, Zilli A, Parigi TL, Peyrin-Biroulet L, Danese S, Allocca M. Advancing Therapeutic Targets in IBD: Emerging Goals and Precision Medicine Approaches. Pharmaceuticals (Basel). 2025 Jan 10;18(1):78. doi: 10.3390/ph18010078. 
  175. D’Amico F, Bencardino S, Gonçalves A, Allocca M, Furfaro F, Zilli A, Parigi TL, Fiorino G, PeyrinBiroulet L, Danese S. Unlocking hope: The future of ustekinumab biosimilars in Crohn’s disease treatment. United European Gastroenterol J. 2025 Feb 18. doi: 10.1002/ueg2.12682.
  176. Altieri G, Zilli A, Parigi TL, Allocca M, Furfaro F, Fiorino G, Cicerone C, Peyrin-Biroulet L, Danese S, D’Amico F. Dual Therapy in Inflammatory Bowel Disease. Biomolecules. 2025 Feb 3;15(2):222. doi: 10.3390/biom15020222.
  177. Vujasinovic M, Iglesia D, Dominguez-Muñoz JE, Löhr JM; European PEI Multidisciplinary Group. Recommendations from the European guidelines for the diagnosis and therapy of pancreatic exocrine insufficiency. Pancreatology. 2025 Feb 28:S1424-3903(25)00043-2. doi: 10.1016/j.pan.2025.02.01

     

Collaborazioni

  1. Tursi A, Brandimarte G, Di Mario F, et al. The DICA Endoscopic Classification for Diverticular Disease of the Colon Shows a Significant Interobserver Agreement among Community Endoscopists: an International Study. J Gastrointestin Liver Dis. 2019;28(suppl. 4):39-44. Published 2019 Dec 19. doi:10.15403/jgld-558 IF: 2.351
  2. Rubin DT, Abreu MT, Rai V, Siegel CA; International Organization for the Study of Inflammatory Bowel Disease. Management of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. Gastroenterology. 2020;159(1):6-13.e6. doi:10.1053/j.gastro.2020.04.002 IF: 22.682
Dottor Ferdinando d'amico

Medico gastroenterologo dell’Unità di Gastroenterologia ed Endoscopia Digestiva dell’IRCCS Ospedale San Raffaele.

Linkedin Twitter Facebook

Link utili

Sedi e contatti

  • Ospedale San Raffaele
  • Via Olgettina, 60 - Milano
  • mail: informazioni@hsr.it

 Tel: 0226432643

©2025 Ferdinando D'Amico | Tutti i diritti riservati